In a stroke, every minute without treatment destroys nearly two million brain cells. RapidAI is the clinical AI platform that cuts the time between scan and decision down to seconds.
Photo source:
rapidai.com
When a patient arrives at a hospital with
stroke symptoms, the clock starts immediately. Brain tissue is dying. Every
minute spent waiting for a scan to be reviewed, a specialist to be contacted, a
team to be assembled, is a minute of permanent neurological damage. The
traditional workflow asks a lot of humans under extreme pressure. A radiologist
reads the scan. A neurologist is called. A treatment decision is made. Each
handoff takes time that the patient does not have. RapidAI was built to
compress that entire chain into seconds.
Most medical AI stops at flagging anomalies. RapidAI goes significantly further. The
platform analyses imaging scans across six distinct clinical layers
simultaneously. It triages suspected cases in real time, localises regions of
concern within the scan, quantifies key metrics like blood flow and anomaly
growth automatically, characterises severity and morphology, generates
automated 3D renderings, and tracks changes longitudinally over time. For a
physician reviewing a stroke case, that means arriving at a decision not with a
raw scan and a question but with a complete clinical picture already assembled.
The difference between those two starting points is measured in outcomes.
The Rapid Enterprise Platform covers four
critical clinical areas. Neurovascular care including ischemic stroke,
hemorrhagic stroke, and aneurysm detection. Cardiac and vascular conditions
including pulmonary embolism and aortic emergencies. Radiology workflow
prioritisation through Navigator Pro. And life sciences clinical trial patient
enrollment. Thirty FDA cleared modules run across more than 2,500 hospitals in
over 100 countries, processing more than 20,000 scans every day. A mobile app
keeps physicians connected to critical cases from the emergency room to the
operating room, sending real-time alerts, enabling cross-team messaging, and
initiating procedural workflows with a single touch. When a rural hospital in
Missouri with no on-site neurologist receives a stroke patient at midnight,
RapidAI gives the attending physician the same clinical intelligence available
at a major academic medical centre.
The platform is supported by more than 700
published studies and 25 clinical trials, making it one of the most rigorously
validated clinical AI systems in the field. Eleven of those publications
appeared in the New England Journal of Medicine. That volume of peer-reviewed
evidence means every clinical claim the platform makes about detection
accuracy, workflow improvement, and patient outcomes is traceable to real data
from real cases across real hospital environments. It is not a promising
technology waiting to be proven. It is a proven technology already operating at
scale.
Please subscribe to have unlimited access to our innovations.